BioCryst Pharmaceuticals Reports Q3 Earnings Beat on Strong Revenue Growth
BioCryst Pharmaceuticals (BCRX) reported third-quarter financial results that exceeded analyst expectations, posting a GAAP EPS of $0.14, which beat estimates by $0.06. The company's revenue reached $180.29 million, representing a 13.1% increase year-over-year and surpassing consensus estimates by $14.61 million. Looking ahead, the company provided updated full-year guidance, maintaining its ORLADEYO revenue outlook between $625 million and $645 million. Total annual revenue is now projected to fall between $715 million and $730 million, up from previous estimates of $690 million to $715 million. Non-GAAP operating expenses are expected to range from $415 million to $425 million.
Tickers: $BCRX
Topics: earnings beat financial guidance pharmaceuticals revenue growth